Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Adjuvant injection therapies following knee cartilage repair demonstrate heterogeneous evidence: A systematic review

Saráchaga Mendoza MA., Niemeyer P., Bumberger A., Angele P., Roessler PP.

Systematic Review with a reported sample of 531 on Osteoarthritis, Cartilage Damage, published in J Exp Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
J Exp Orthop (2025)
Reported sample size
531
Source database
Europe PMC
PMID
41245709
PMCID
PMC12616273
DOI
10.1002/jeo2.70555

Abstract (original English)

Purpose The objective of this study was to systematically review the existing literature related to adjuvant injection therapies among patients with cartilage defects of the knee joint who have undergone bone marrow stimulation procedures and ascertain their potential clinical benefits. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a search was conducted on PubMed and the Cochrane Library to identify articles documenting the utilization of adjuvant injection therapies after surgery for cartilage defects, with a minimum short-term follow-up. Animal studies, uncontrolled trials, studies lacking primary surgical intervention or those including patients with osteoarthritis were excluded. Results Twelve articles focusing on knee cartilage defects were analysed (531 patients). Platelet-rich plasma was used in eight studies, mesenchymal stromal cells in four and hyaluronic acid in one. Injection frequency and timing varied, with the most common timing being during surgery. Primary outcome measures included subjective International Knee Documentation Committee (IKDC) and Visual Analogue Scale (VAS) scores. Subjective IKDC showed significant difference in five out of nine studies and VAS in three out of eight studies, favouring injection therapy groups. Conclusion The present review demonstrates a large heterogeneity among

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research